Literature DB >> 22729154

Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection.

James J Goedert1, Mark Bower.   

Abstract

PURPOSE OF REVIEW: To estimate the impact of highly effective antiretroviral therapy (ART) on the incidence and prognosis of Hodgkin lymphoma among people with human immunodeficiency virus infection or AIDS (PWHA). RECENT
FINDINGS: Age-adjusted incidence of Hodgkin lymphoma in PWHA is unchanged and is still five-fold to fifteen-fold higher than in the general population. Aging of the PWHA population with ART may account for increasing numbers of Hodgkin lymphoma cases. CD4 cell count has a complex relationship to Hodgkin lymphoma risk in PWHA. Depending on the time of measurement, Hodgkin lymphoma risk is highest with 50-249 CD4 cells/μl, and falling CD4 count on ART may be a harbinger of Hodgkin lymphoma onset. HIV load appears irrelevant to Hodgkin lymphoma. For obscure reasons, Hodgkin lymphoma risk may be elevated soon after starting ART, but the risk is probably modestly reduced with 6 or more months on ART. For PWHA who develop Hodgkin lymphoma, ART and ABVD chemotherapy can be administered safely, with one recent study demonstrating equivalent outcomes for HIV-positive and HIV-negative Hodgkin lymphoma patients.
SUMMARY: Vigilance for Hodgkin lymphoma is needed for immune-deficient PWHA, including those on ART. ART with opportunistic infection prophylaxis enables the delivery of effective chemotherapy for Hodgkin lymphoma, leading to a good prognosis.

Entities:  

Mesh:

Year:  2012        PMID: 22729154      PMCID: PMC3604881          DOI: 10.1097/CCO.0b013e3283560697

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  22 in total

1.  HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy.

Authors:  Emilie Lanoy; Philip S Rosenberg; Fabien Fily; Anne-Sophie Lascaux; Valerie Martinez; Maria Partisani; Isabelle Poizot-Martin; Elisabeth Rouveix; Eric A Engels; Dominique Costagliola; James J Goedert
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

2.  Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data.

Authors:  S L Glaser; R J Lin; S L Stewart; R F Ambinder; R F Jarrett; P Brousset; G Pallesen; M L Gulley; G Khan; J O'Grady; M Hummel; M V Preciado; H Knecht; J K Chan; A Claviez
Journal:  Int J Cancer       Date:  1997-02-07       Impact factor: 7.396

3.  Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS.

Authors:  Robert J Biggar; Elaine S Jaffe; James J Goedert; Anil Chaturvedi; Ruth Pfeiffer; Eric A Engels
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

4.  HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes.

Authors:  Julia Bohlius; Kurt Schmidlin; François Boué; Gerd Fätkenheuer; Margaret May; Ana Maria Caro-Murillo; Amanda Mocroft; Fabrice Bonnet; Gary Clifford; Vassilios Paparizos; Jose M Miro; Niels Obel; Maria Prins; Geneviève Chêne; Matthias Egger
Journal:  Blood       Date:  2011-03-02       Impact factor: 22.113

Review 5.  Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions.

Authors:  E Klein; L L Kis; G Klein
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

6.  Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience.

Authors:  N Rosdahl; S O Larsen; J Clemmesen
Journal:  Br Med J       Date:  1974-05-04

7.  Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998.

Authors:  Sally L Glaser; Christina A Clarke; Margaret L Gulley; Fiona E Craig; Joseph A DiGiuseppe; Ronald F Dorfman; Risa B Mann; Richard F Ambinder
Journal:  Cancer       Date:  2003-07-15       Impact factor: 6.860

8.  AIDS-related cancer and severity of immunosuppression in persons with AIDS.

Authors:  Robert J Biggar; Anil K Chaturvedi; James J Goedert; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2007-06-12       Impact factor: 13.506

9.  Prompt versus preemptive intervention for EBV lymphoproliferative disease.

Authors:  Hans-Joachim Wagner; Yee Chung Cheng; M Helen Huls; Adrian P Gee; Ingrid Kuehnle; Robert A Krance; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2004-01-29       Impact factor: 22.113

Review 10.  Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence.

Authors:  H Hjalgrim; E A Engels
Journal:  J Intern Med       Date:  2008-12       Impact factor: 8.989

View more
  15 in total

Review 1.  Screening for Cancer in Persons Living with HIV Infection.

Authors:  James J Goedert; H Dean Hosgood; Robert J Biggar; Howard D Strickler; Charles S Rabkin
Journal:  Trends Cancer       Date:  2016-08

Review 2.  Impact of Antiretroviral Therapy on Cancer Treatment Outcomes among People Living with HIV in Low- and Middle-Income Countries: a Systematic Review.

Authors:  Michalina A Montaño; Maganizo B Chagomerana; Margaret Borok; Matthew Painschab; Thomas S Uldrick; Rachel A Bender Ignacio
Journal:  Curr HIV/AIDS Rep       Date:  2021-02-02       Impact factor: 5.071

3.  Long-Term Survival Rates of Patients with Stage III-IV Hodgkin Lymphoma According to Age, Sex, Race, and Socioeconomic Status, 1984-2013.

Authors:  Yushi Li; Huanhuan Sun; Yan Yan; Tiantian Sun; Shuncong Wang; Haiqing Ma
Journal:  Oncologist       Date:  2018-05-08

Review 4.  The role of viral co-infection in HIV-associated non-AIDS-related cancers.

Authors:  David J Riedel; Lydia S Tang; Anne F Rositch
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

5.  Thoracic diseases associated with HIV infection in the era of antiretroviral therapy: clinical and imaging findings.

Authors:  Shinn-Huey S Chou; Somnath J Prabhu; Kristina Crothers; Eric J Stern; J David Godwin; Sudhakar N Pipavath
Journal:  Radiographics       Date:  2014 Jul-Aug       Impact factor: 5.333

Review 6.  Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals.

Authors:  Xionghao Lin; Tatyana Ammosova; Namita Kumari; Sergei Nekhai
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

Review 7.  Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk.

Authors:  Alvaro H Borges; Robert Dubrow; Michael J Silverberg
Journal:  Curr Opin HIV AIDS       Date:  2014-01       Impact factor: 4.283

8.  Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1.

Authors:  Mudit Tyagi; Sergey Iordanskiy; Tatyana Ammosova; Namita Kumari; Kahli Smith; Denitra Breuer; Andrey V Ilatovskiy; Yasemin Saygideğer Kont; Andrey Ivanov; Aykut Üren; Dmytro Kovalskyy; Michael Petukhov; Fatah Kashanchi; Sergei Nekhai
Journal:  Retrovirology       Date:  2015-07-16       Impact factor: 4.602

Review 9.  Epstein-Barr virus and the origin of Hodgkin lymphoma.

Authors:  Martina Vockerodt; Fathima Zumla Cader; Claire Shannon-Lowe; Paul Murray
Journal:  Chin J Cancer       Date:  2014-11-21

10.  Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol.

Authors:  Tarig Mohammed Abkur; Mamoun Saeed; Saad Zeinalabdin Ahmed; Ryan McArthur; Maeve Leahy; Hilary O'Leary; Denis O'Keeffe
Journal:  Clin Case Rep       Date:  2015-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.